食物过敏治疗市场－全球产业规模、份额、趋势、机会及预测（依过敏原类型、药物类型、给药途径、最终用户、地区和竞争格局划分，2021-2031年）

全球食物过敏治疗市场预计将从 2025 年的 71.5 亿美元成长到 2031 年的 115.3 亿美元，复合年增长率达到 8.29%。

该领域涉及药物干预和免疫疗法的研发和商业化，旨在降低免疫系统的敏感性，并控制由特定食物蛋白引发的急性过敏反应。推动这一领域成长的关键因素是全球范围内对花生、牛奶和鸡蛋等过敏原的致敏率迅速​​上升，这使得人们对有效的临床管理策略（而不仅仅是避免接触过敏原）的需求显着增加。此外，近期生物製药製剂的核准上市也大大促进了该领域的发展，为医疗保健提供者提供了一种降低过敏反应严重程度的新机制。

然而，这个市场面临着许多障碍，包括新型治疗方法的高成本和复杂的报销机制，这些因素常常限制了患者的广泛获取。这些经济障碍阻碍了不同人群公平地获得改变人生的治疗方法。根据美国食品过敏研究与教育组织（FARE）2024年的报告显示，美国约有3,300万人患有危及生命的食物过敏，这凸显了巨大的潜在市场，但其发展仍部分受限于价格承受能力方面的挑战。

市场驱动因素

创新免疫疗法和生物製药的快速普及正在从根本上改变全球食物过敏治疗市场，使临床治疗不再局限于权宜之计。这项转变得益于近期监管方面的进展，为医疗专业人员提供了第一个能够同时减轻多种过敏原反应严重程度的药物选择。例如，在2024年2月发布的新闻稿《FDA核准Zolia成为首个也是目前唯一一个用于治疗儿童和成人一种或多种食物过敏的药物》中，基因泰克公司报告称，临床试验表明，接受Zolia治疗16至20週的患者中，68%能够耐受至少600毫克花生蛋白而无中度至重度症状，而安慰剂组仅有标准。如此显着的疗效数据促使生物製药迅速整合到标准治疗通讯协定中，直接扩大了治疗性介入的潜在市场。

同时，儿童和成人严重食物过敏在全球范围内的日益普遍，也使得这些缓解疾病治疗方法的研发变得尤为迫切。面临生命危险的患者群体的存在显着影响着市场趋势，导致预防过敏性休克的治疗方法存在着巨大的未满足需求。根据美国疾病管制与预防中心 (CDC) 2024 年的数据，至少 40% 的食物过敏儿童因过敏反应而在急诊室接受治疗，凸显了疾病的严重性。如此沉重的疾病负担正在推动大量的商业活动和研发投入。正如 DBV Technologies 在 2024 年 11 月发布的「2024 年第三季财报」中所述，该公司年初至今的营运支出预计将达到 9,640 万美元，其中大部分将用于支持关键性临床试验的推进。

市场挑战

全球食物过敏治疗市场的商业性扩张受到新型治疗方法高成本和复杂的健保报销环境的显着阻碍。儘管药物研发的进步带来了新的脱敏机制，但这些生物製药生产商收取高昂的标价。因此，医疗保险公司通常将这些治疗方法归类为非必需疗法，或将其列入高额自付费用等级，从而造成经济障碍，限制了患者的接受度。临床可近性和经济可负担性之间的这种差距限制了潜在市场规模，因为只有一小部分确诊患者能够负担得起持续的治疗费用，从而抑制了生产商的收入成长。

这种经济摩擦因受这些疾病影响的家庭本已承受的经济负担而进一步加剧。根据美国气喘和过敏基金会 (AAFA) 2025 年的预测，经通​​货膨胀调整后，每年照顾食物过敏儿童的经济成本约为 340 亿美元。这一惊人的数字表明，这些家庭已经承受着沉重的经济负担，而昂贵的药物治疗费用对许多家庭来说更是难以承受。因此，市场难以将高昂的临床需求转化为持续的治疗普及。

市场趋势

随着无针替代方案（尤其是鼻用肾上腺素喷雾剂）的商业化，急救领域正在经历重大变革，这些方案正在取代传统的自动注射器。这一趋势直接解决了诸如对针头的恐惧和笨重设备的使用障碍等重大问题，这些问题曾导致在过敏性休克发作期间救命药物的给药延误。製造商目前正利用积极的定价策略和合作模式，以确保这些新型给药系统能够快速渗透市场并惠及广大患者。例如，根据 GoodRx 于 2024 年 9 月发布的题为「neffy 宣布零售药局最低现金折扣价」的新闻稿，一项策略合作将使超过 7 万家药局能够以 199 美元的价格购买两支装的 neffy 一次性装置，从而显着降低这项新技术带来的经济门槛。

同时，经皮免疫疗法（EPIT）平台的研发正蓬勃发展。该平台透过皮肤给药微量抗原，诱导免疫耐受，且全身副作用比口服途径更少。这种非侵入性疗法正迅速推进至后期临床开发阶段，旨在为可能无法耐受口服免疫疗法相关胃肠道副作用的儿童患者提供更安全的脱敏方案。 DBV Technologies 在 2024 年 10 月的新闻稿「DBV 宣布 Viaskin 花生贴片监管审批取得积极进展」中，反映了该临床开发的规模。新闻稿中指出，该公司已完成对改良花生贴片在儿童中疗效评估的 III 期 VITESSE 试验的受试者招募，总合招募了 654 名受试者。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球食物过敏治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依过敏原分类（乳製品、家禽、坚果、花生、贝类、小麦、大豆、其他）
  • 依药物类型（抗组织胺药物、肾上腺素、免疫疗法）
  • 依给药途径（口服、肠外、其他）
  • 依最终用户（医院药局、零售药局、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美食物过敏治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲食物过敏治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区食物过敏治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲食物过敏治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲食物过敏治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球食物过敏治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Aimmune Therapeutics
• DBV Technologies
• Regeneron
• Sanofi
• Nestle Health Science
• Novartis
• Immune Design
• TanGenix
• Allergen Labs
• 与FARE相关的创新者

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Food Allergy Treatment Market is projected to expand from USD 7.15 Billion in 2025 to USD 11.53 Billion by 2031, achieving a CAGR of 8.29%. This sector encompasses the development and commercialization of pharmaceutical interventions and immunotherapies aimed at desensitizing the immune system or managing acute anaphylactic reactions triggered by specific dietary proteins. The primary force driving this growth is the rapidly rising global prevalence of sensitization to allergens like peanuts, milk, and eggs, which creates a critical demand for effective clinical management strategies beyond simple avoidance. Furthermore, the recent regulatory approval and launch of biologic agents that facilitate desensitization are significantly boosting the sector by offering healthcare providers new mechanisms to reduce the severity of allergic reactions.

However, the market confronts a major obstacle regarding the high cost of new therapies and a complicated reimbursement environment that frequently limits broad patient access. These financial hurdles often obstruct the equitable availability of life-altering treatments across various demographic groups. As reported by Food Allergy Research & Education in 2024, approximately 33 million individuals in the United States were living with life-threatening food allergies, underscoring a massive addressable market that remains partially restricted by affordability challenges.

Market Driver

The rapid adoption of innovative immunotherapies and biologics is fundamentally transforming the Global Food Allergy Treatment Market, shifting clinical care beyond mere avoidance tactics. This evolution is underpinned by recent regulatory achievements that provide medical professionals with the first pharmaceutical options capable of reducing reaction severity across multiple allergens simultaneously. For instance, Genentech reported in a February 2024 press release titled 'FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies' that clinical trials showed 68% of patients treated with Xolair for 16 to 20 weeks could tolerate at least 600 mg of peanut protein without moderate to severe symptoms, compared to only 5% of the placebo group. Such strong efficacy data encourages the swift integration of biologic agents into standard treatment protocols, directly broadening the addressable market for therapeutic interventions.

Simultaneously, the increasing global prevalence of severe food allergies in both children and adults is heightening the urgency for these disease-modifying solutions. The market's trajectory is heavily influenced by a patient population facing life-threatening risks, resulting in a critical unmet need for treatments that prevent anaphylaxis. Data from the Centers for Disease Control and Prevention in 2024 indicates that at least 40% of children with food allergies have been treated in the emergency department for reactions, highlighting the condition's severity. This significant disease burden drives substantial commercial activity and development spending; as noted by DBV Technologies in their 'Third Quarter 2024 Financial Results' from November 2024, operating expenses reached $96.4 million for the first nine months of the year, primarily to support the advancement of pivotal clinical trials.

Market Challenge

The commercial expansion of the Global Food Allergy Treatment Market is significantly hindered by the high cost of novel therapies and a complex reimbursement landscape. Although pharmaceutical advancements provide new desensitization mechanisms, the extensive research and development investments required for these biologics compel manufacturers to set premium list prices. Consequently, health insurers often categorize these treatments as non-essential or place them in tiers with high out-of-pocket costs, creating a financial barrier that restricts patient adoption. This gap between clinical availability and economic accessibility limits the serviceable addressable market, as only a fraction of the diagnosed population can afford continuous therapy, thereby stalling revenue growth for manufacturers.

This financial friction is further exacerbated by the existing economic burden placed on families managing these conditions. The Asthma and Allergy Foundation of America estimated in 2025 that the inflation-adjusted annual economic cost of caring for children with food allergies was approximately $34 billion. This substantial figure illustrates the heavy financial load already borne by households, making the additional expense of high-priced pharmaceutical interventions untenable for many. As a result, the market struggles to convert high clinical demand into sustained therapeutic adoption.

Market Trends

The emergency response segment is undergoing a significant transition from traditional auto-injectors to needle-free alternatives, specifically with the commercialization of intranasal epinephrine sprays. This trend directly targets critical barriers such as needle phobia and device bulkiness, which have historically delayed the administration of life-saving medication during anaphylactic events. Manufacturers are currently utilizing aggressive pricing strategies and partnership models to ensure these novel delivery systems rapidly penetrate the market and become accessible to a broad patient base. For example, according to a September 2024 press release by GoodRx titled 'GoodRx Announces Lowest Discounted Cash Price at Retail Pharmacy Locations for neffy,' a strategic partnership was established to allow consumers to access a pack of two single-use neffy devices for $199 at over 70,000 pharmacies, significantly lowering the financial hurdle for this new technology.

At the same time, the market is seeing a surge in the development of Epicutaneous Immunotherapy (EPIT) platforms, which deliver micro-doses of allergens through the skin to induce tolerance with fewer systemic side effects than oral routes. This non-invasive approach is rapidly moving through late-stage clinical pipelines, aiming to provide a safer desensitization option for pediatric patients who may not tolerate the gastrointestinal side effects associated with oral immunotherapy. Reflecting the substantial scale of this clinical development, DBV Technologies announced in an October 2024 press release titled 'DBV Announces Positive Regulatory Updates for the Viaskin Peanut Patch' that the company successfully enrolled a total of 654 subjects in the Phase 3 VITESSE efficacy trial to evaluate the modified peanut patch in children.

Key Market Players

• Aimmune Therapeutics
• DBV Technologies
• Regeneron
• Sanofi
• Nestle Health Science
• Novartis
• Immune Design
• TanGenix
• Allergen Labs
• FARE-associated Innovators

Report Scope

In this report, the Global Food Allergy Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Food Allergy Treatment Market, By Allergen Type

• Dairy Products
• Poultry Product
• Tree Nuts
• Peanuts
• Shellfish
• Wheat
• Soys
• Other

Food Allergy Treatment Market, By Drug Type

• Antihistamines
• Epinephrine
• Immunotherapy

Food Allergy Treatment Market, By Route of Administration

• Oral
• Parenteral
• Other

Food Allergy Treatment Market, By End User

• Hospital Pharmacies
• Retail Pharmacies
• Others

Food Allergy Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Food Allergy Treatment Market.

Available Customizations:

Global Food Allergy Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Food Allergy Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Allergen Type (Dairy Products, Poultry Product, Tree Nuts, Peanuts, Shellfish, Wheat, Soys, Other)
  • 5.2.2. By Drug Type (Antihistamines, Epinephrine, Immunotherapy)
  • 5.2.3. By Route of Administration (Oral, Parenteral, Other)
  • 5.2.4. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Food Allergy Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Allergen Type
  • 6.2.2. By Drug Type
  • 6.2.3. By Route of Administration
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Food Allergy Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Allergen Type
      • 6.3.1.2.2. By Drug Type
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Food Allergy Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Allergen Type
      • 6.3.2.2.2. By Drug Type
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Food Allergy Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Allergen Type
      • 6.3.3.2.2. By Drug Type
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By End User

7. Europe Food Allergy Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Allergen Type
  • 7.2.2. By Drug Type
  • 7.2.3. By Route of Administration
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Food Allergy Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Allergen Type
      • 7.3.1.2.2. By Drug Type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By End User
  • 7.3.2. France Food Allergy Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Allergen Type
      • 7.3.2.2.2. By Drug Type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Food Allergy Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Allergen Type
      • 7.3.3.2.2. By Drug Type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Food Allergy Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Allergen Type
      • 7.3.4.2.2. By Drug Type
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Food Allergy Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Allergen Type
      • 7.3.5.2.2. By Drug Type
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By End User

8. Asia Pacific Food Allergy Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Allergen Type
  • 8.2.2. By Drug Type
  • 8.2.3. By Route of Administration
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Food Allergy Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Allergen Type
      • 8.3.1.2.2. By Drug Type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By End User
  • 8.3.2. India Food Allergy Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Allergen Type
      • 8.3.2.2.2. By Drug Type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Food Allergy Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Allergen Type
      • 8.3.3.2.2. By Drug Type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Food Allergy Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Allergen Type
      • 8.3.4.2.2. By Drug Type
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Food Allergy Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Allergen Type
      • 8.3.5.2.2. By Drug Type
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By End User

9. Middle East & Africa Food Allergy Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Allergen Type
  • 9.2.2. By Drug Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Food Allergy Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Allergen Type
      • 9.3.1.2.2. By Drug Type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Food Allergy Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Allergen Type
      • 9.3.2.2.2. By Drug Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Food Allergy Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Allergen Type
      • 9.3.3.2.2. By Drug Type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By End User

10. South America Food Allergy Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Allergen Type
  • 10.2.2. By Drug Type
  • 10.2.3. By Route of Administration
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Food Allergy Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Allergen Type
      • 10.3.1.2.2. By Drug Type
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Food Allergy Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Allergen Type
      • 10.3.2.2.2. By Drug Type
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Food Allergy Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Allergen Type
      • 10.3.3.2.2. By Drug Type
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Food Allergy Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Aimmune Therapeutics
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. DBV Technologies
• 15.3. Regeneron
• 15.4. Sanofi
• 15.5. Nestle Health Science
• 15.6. Novartis
• 15.7. Immune Design
• 15.8. TanGenix
• 15.9. Allergen Labs
• 15.10. FARE-associated Innovators

16. Strategic Recommendations

17. About Us & Disclaimer